ANIP
ANI Pharmaceuticals, Inc.$81.54-0.11 (-0.13%)Prev Close$81.65·MCap$1.86B·P/E20.70·Vol135.0K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
63
$57.01M
◆
Net Activity
Net Seller
$57.01M
●
Active Insiders
15
last 12 mo
Over the past 12 months, insider activity at ANI Pharmaceuticals, Inc. (ANIP) has been exclusively selling, with 0 insider purchases totaling $0.00 and 63 insider sales totaling $57.01M. The most recent insider transaction was by HAUGHEY THOMAS (director), who sold $161.8K worth of shares on Jun 10, 2026. ANI Pharmaceuticals, Inc. operates in the Healthcare sector, within the Drug Manufacturers - Specialty & Generic industry, with a market cap of $1.86B.
ANIP Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 10, 2026 | HAUGHEY THOMAS | director | Sell | 2,000 | $80.88 | $161.8K | 38,878 |
| Jun 9, 2026 | CAREY STEPHEN P. | officer: SVP & CFO | Sell | 3,312 | $80.00 | $265.0K | 180,393 |
| May 13, 2026 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $78.16 | $39.1K | 78,390 |
| May 13, 2026 | Gutwerg Ori | officer: SVP, GENERICS | Sell | 2,772 | $79.50 | $220.4K | 78,696 |
| May 13, 2026 | Lalwani Nikhil | director, officer: PRESIDENT & CEO | Sell | 55,000 | $77.57 | $4.27M | 349,889 |
| May 13, 2026 | Rowland Thomas Andrew | officer: SVP, HEAD - ESTABLISHED BRANDS | Sell | 459 | $79.21 | $36.4K | 38,271 |
| May 13, 2026 | Walsh Patrick D | director | Sell | 13,973 | $80.66 | $1.13M | 48,432 |
| Apr 13, 2026 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $77.95 | $39.0K | 78,890 |
| Mar 13, 2026 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $72.62 | $36.3K | 79,390 |
| Mar 13, 2026 | Mutz Christopher | officer: HEAD OF RARE DISEASE | Sell | 3,162 | $71.64 | $226.5K | 91,309 |
| Mar 13, 2026 | Rowland Thomas Andrew | officer: SVP, HEAD - ESTABLISHED BRANDS | Sell | 4,772 | $74.91 | $357.5K | 38,730 |
| Mar 10, 2026 | Davis Krista | officer: SVP, CHIEF HR OFFICER | Sell | 6,572 | $74.33 | $488.5K | 57,033 |
| Mar 10, 2026 | Mutz Christopher | officer: HEAD OF RARE DISEASE | Sell | 5,723 | $74.19 | $424.6K | 101,387 |
| Mar 5, 2026 | CAREY STEPHEN P. | officer: SVP & CFO | Sell | 7,312 | $75.50 | $552.0K | 189,543 |
| Feb 20, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 5,323 | $78.02 | $415.3K | 0 |
| Feb 19, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 3,814 | $77.74 | $296.5K | 0 |
| Feb 17, 2026 | CAREY STEPHEN P. | SVP & CFO | Sell | 5,277 | $77.01 | $406.4K | 0 |
| Feb 12, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 3,813 | $77.02 | $293.7K | 0 |
| Feb 12, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 2,470 | $77.04 | $190.3K | 0 |
| Feb 12, 2026 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 3,325 | $77.04 | $256.2K | 0 |
| Feb 12, 2026 | Gutwerg Ori | SVP, GENERICS | Sell | 3,663 | $77.04 | $282.2K | 0 |
| Feb 12, 2026 | Lalwani Nikhil | PRESIDENT & CEO | Sell | 21,986 | $77.01 | $1.69M | 0 |
| Feb 12, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 12,608 | $76.74 | $967.6K | 0 |
| Feb 12, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Sell | 1,051 | $77.00 | $80.9K | 0 |
| Feb 11, 2026 | CAREY STEPHEN P. | SVP & CFO | Sell | 5,503 | $76.25 | $419.6K | 0 |
| Feb 11, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 3,011 | $76.25 | $229.6K | 0 |
| Feb 11, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 3,017 | $76.25 | $230.0K | 0 |
| Feb 11, 2026 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 4,269 | $76.25 | $325.5K | 0 |
| Feb 11, 2026 | Gutwerg Ori | SVP, GENERICS | Sell | 4,267 | $76.25 | $325.4K | 0 |
| Feb 11, 2026 | Lalwani Nikhil | PRESIDENT & CEO | Sell | 30,659 | $76.25 | $2.34M | 0 |
| Feb 11, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 4,546 | $76.25 | $346.6K | 0 |
| Feb 11, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Sell | 1,762 | $76.25 | $134.4K | 0 |
| Feb 11, 2026 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 2,898 | $76.25 | $221.0K | 0 |
| Jan 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $84.33 | $42.2K | 0 |
| Dec 18, 2025 | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,622 | $82.40 | $133.7K | 0 |
| Dec 12, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $82.32 | $32.9K | 0 |
| Dec 5, 2025 | TANNENBAUM RENEE P | Director | Sell | 1,800 | $81.15 | $146.1K | 0 |
| Nov 13, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $87.27 | $34.9K | 0 |
| Nov 13, 2025 | Walsh Patrick D | Director | Sell | 8,643 | $86.88 | $750.9K | 0 |
| Nov 12, 2025 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 14,736 | $89.06 | $1.31M | 0 |
| Oct 13, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $90.09 | $36.0K | 0 |
| Sep 19, 2025 | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,000 | $98.04 | $98.0K | 0 |
| Sep 12, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $98.42 | $39.4K | 0 |
| Sep 12, 2025 | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,710 | $97.71 | $167.1K | 0 |
| Sep 3, 2025 | Pera Antonio R | Director | Sell | 7,292 | $94.94 | $692.3K | 0 |
| Aug 25, 2025 | Leonard Matthew J | Director | Sell | 2,528 | $90.62 | $229.1K | 0 |
| Aug 22, 2025 | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,763 | $91.10 | $160.6K | 0 |
| Aug 20, 2025 | Pera Antonio R | Director | Sell | 5,421 | $89.73 | $486.4K | 0 |
| Aug 20, 2025 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 100,000 | $90.36 | $9.04M | 0 |
| Aug 18, 2025 | Leonard Matthew J | Director | Sell | 6,937 | $88.17 | $611.6K | 0 |
Showing 1–50 of 229
1 / 5
ANIP Insider Buying Activity
The following table shows recent insider purchases of ANI Pharmaceuticals, Inc. (ANIP) stock reported via SEC Form 4 filings.
No insider buying activity found for ANIP in the last 12 months.
ANIP Insider Selling Activity
The following table shows recent insider sales of ANI Pharmaceuticals, Inc. (ANIP) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 10, 2026 | HAUGHEY THOMAS | director | Sell | 2,000 | $80.88 | $161.8K | 38,878 |
| Jun 9, 2026 | CAREY STEPHEN P. | officer: SVP & CFO | Sell | 3,312 | $80.00 | $265.0K | 180,393 |
| May 13, 2026 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $78.16 | $39.1K | 78,390 |
| May 13, 2026 | Gutwerg Ori | officer: SVP, GENERICS | Sell | 2,772 | $79.50 | $220.4K | 78,696 |
| May 13, 2026 | Lalwani Nikhil | director, officer: PRESIDENT & CEO | Sell | 55,000 | $77.57 | $4.27M | 349,889 |
| May 13, 2026 | Rowland Thomas Andrew | officer: SVP, HEAD - ESTABLISHED BRANDS | Sell | 459 | $79.21 | $36.4K | 38,271 |
| May 13, 2026 | Walsh Patrick D | director | Sell | 13,973 | $80.66 | $1.13M | 48,432 |
| Apr 13, 2026 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $77.95 | $39.0K | 78,890 |
| Mar 13, 2026 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $72.62 | $36.3K | 79,390 |
| Mar 13, 2026 | Mutz Christopher | officer: HEAD OF RARE DISEASE | Sell | 3,162 | $71.64 | $226.5K | 91,309 |
| Mar 13, 2026 | Rowland Thomas Andrew | officer: SVP, HEAD - ESTABLISHED BRANDS | Sell | 4,772 | $74.91 | $357.5K | 38,730 |
| Mar 10, 2026 | Davis Krista | officer: SVP, CHIEF HR OFFICER | Sell | 6,572 | $74.33 | $488.5K | 57,033 |
| Mar 10, 2026 | Mutz Christopher | officer: HEAD OF RARE DISEASE | Sell | 5,723 | $74.19 | $424.6K | 101,387 |
| Mar 5, 2026 | CAREY STEPHEN P. | officer: SVP & CFO | Sell | 7,312 | $75.50 | $552.0K | 189,543 |
| Feb 20, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 5,323 | $78.02 | $415.3K | 0 |
| Feb 19, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 3,814 | $77.74 | $296.5K | 0 |
| Feb 17, 2026 | CAREY STEPHEN P. | SVP & CFO | Sell | 5,277 | $77.01 | $406.4K | 0 |
| Feb 12, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 3,813 | $77.02 | $293.7K | 0 |
| Feb 12, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 2,470 | $77.04 | $190.3K | 0 |
| Feb 12, 2026 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 3,325 | $77.04 | $256.2K | 0 |
| Feb 12, 2026 | Gutwerg Ori | SVP, GENERICS | Sell | 3,663 | $77.04 | $282.2K | 0 |
| Feb 12, 2026 | Lalwani Nikhil | PRESIDENT & CEO | Sell | 21,986 | $77.01 | $1.69M | 0 |
| Feb 12, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 12,608 | $76.74 | $967.6K | 0 |
| Feb 12, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Sell | 1,051 | $77.00 | $80.9K | 0 |
| Feb 11, 2026 | CAREY STEPHEN P. | SVP & CFO | Sell | 5,503 | $76.25 | $419.6K | 0 |
| Feb 11, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 3,011 | $76.25 | $229.6K | 0 |
| Feb 11, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 3,017 | $76.25 | $230.0K | 0 |
| Feb 11, 2026 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 4,269 | $76.25 | $325.5K | 0 |
| Feb 11, 2026 | Gutwerg Ori | SVP, GENERICS | Sell | 4,267 | $76.25 | $325.4K | 0 |
| Feb 11, 2026 | Lalwani Nikhil | PRESIDENT & CEO | Sell | 30,659 | $76.25 | $2.34M | 0 |
| Feb 11, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 4,546 | $76.25 | $346.6K | 0 |
| Feb 11, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Sell | 1,762 | $76.25 | $134.4K | 0 |
| Feb 11, 2026 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 2,898 | $76.25 | $221.0K | 0 |
| Jan 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $84.33 | $42.2K | 0 |
| Dec 18, 2025 | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,622 | $82.40 | $133.7K | 0 |
| Dec 12, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $82.32 | $32.9K | 0 |
| Dec 5, 2025 | TANNENBAUM RENEE P | Director | Sell | 1,800 | $81.15 | $146.1K | 0 |
| Nov 13, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $87.27 | $34.9K | 0 |
| Nov 13, 2025 | Walsh Patrick D | Director | Sell | 8,643 | $86.88 | $750.9K | 0 |
| Nov 12, 2025 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 14,736 | $89.06 | $1.31M | 0 |
| Oct 13, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $90.09 | $36.0K | 0 |
| Sep 19, 2025 | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,000 | $98.04 | $98.0K | 0 |
| Sep 12, 2025 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 400 | $98.42 | $39.4K | 0 |
| Sep 12, 2025 | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,710 | $97.71 | $167.1K | 0 |
| Sep 3, 2025 | Pera Antonio R | Director | Sell | 7,292 | $94.94 | $692.3K | 0 |
| Aug 25, 2025 | Leonard Matthew J | Director | Sell | 2,528 | $90.62 | $229.1K | 0 |
| Aug 22, 2025 | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 1,763 | $91.10 | $160.6K | 0 |
| Aug 20, 2025 | Pera Antonio R | Director | Sell | 5,421 | $89.73 | $486.4K | 0 |
| Aug 20, 2025 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 100,000 | $90.36 | $9.04M | 0 |
| Aug 18, 2025 | Leonard Matthew J | Director | Sell | 6,937 | $88.17 | $611.6K | 0 |
ANIP Insiders
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
Bought $138.3KSold $59.00M
29 tradesLast: Feb 11, 2026
Similar Stocks to ANIP
VTRS
Viatris Inc.
$16.41+0.71%
$18.55B
ELAN
Elanco Animal Health Incorporated
$24.26+0.87%
$11.83B
AMRX
Amneal Pharmaceuticals, Inc.
$16.39+0.34%
$5.21B
INDV
Indivior Pharmaceuticals Inc
$38.27+0.35%
$4.76B
SUPN
Supernus Pharmaceuticals, Inc.
$44.56-2.17%
$2.64B
HROW
Harrow Health, Inc.
$37.67+0.05%
$1.29B
PAHC
Phibro Animal Health Corporation
$32.05+2.51%
$1.16B
COLL
Collegium Pharmaceutical, Inc.
$34.46+0.35%
$1.06B